65 related articles for article (PubMed ID: 25022336)
21. Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration.
Driessens G; Gordower L; Nuttin L; Stordeur P; Blocklet D; Egrise D; Velu T; Bruyns C
Cancer Immunol Immunother; 2008 Dec; 57(12):1745-56. PubMed ID: 18369621
[TBL] [Abstract][Full Text] [Related]
22. Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer.
Ehtesham M; Samoto K; Kabos P; Acosta FL; Gutierrez MA; Black KL; Yu JS
Cancer Gene Ther; 2002 Nov; 9(11):925-34. PubMed ID: 12386831
[TBL] [Abstract][Full Text] [Related]
23. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
[TBL] [Abstract][Full Text] [Related]
24. Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment.
Jeyanathan M; Mu J; McCormick S; Damjanovic D; Small CL; Shaler CR; Kugathasan K; Xing Z
Am J Respir Crit Care Med; 2010 Apr; 181(8):862-72. PubMed ID: 20019338
[TBL] [Abstract][Full Text] [Related]
25. Interstitial transfer factor as adjuvant immunotherapy for experimental glioma.
Pineda B; Estrada-Parra S; Pedraza-Medina B; Rodriguez-Ropon A; Pérez R; Arrieta O
J Exp Clin Cancer Res; 2005 Dec; 24(4):575-83. PubMed ID: 16471320
[TBL] [Abstract][Full Text] [Related]
26. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
27. Radiation immunomodulatory gene tumor therapy of rats with intracerebral glioma tumors.
Persson BR; Koch CB; Grafström G; Ceberg C; Munckaf Rosenschöld P; Nittby H; Widegren B; Salford LG
Radiat Res; 2010 Apr; 173(4):433-40. PubMed ID: 20334515
[TBL] [Abstract][Full Text] [Related]
28. Interferon-gamma in brain tumor immunotherapy.
Kane A; Yang I
Neurosurg Clin N Am; 2010 Jan; 21(1):77-86. PubMed ID: 19944968
[TBL] [Abstract][Full Text] [Related]
29. Impaired antigen presentation and effectiveness of combined active/passive immunotherapy for epithelial tumors.
Matsumoto K; Leggatt GR; Zhong J; Liu X; de Kluyver RL; Peters T; Fernando GJ; Liem A; Lambert PF; Frazer IH
J Natl Cancer Inst; 2004 Nov; 96(21):1611-9. PubMed ID: 15523090
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity and modified immunoregulation associated with IFN-gamma treatment of RG2 gliomas.
Oshiro S; Fukushima T; Tomonaga M; Black KL
Anticancer Res; 1999; 19(6B):5029-36. PubMed ID: 10697506
[TBL] [Abstract][Full Text] [Related]
32. A mathematical model to elucidate brain tumor abrogation by immunotherapy with T11 target structure.
Banerjee S; Khajanchi S; Chaudhuri S
PLoS One; 2015; 10(5):e0123611. PubMed ID: 25955428
[TBL] [Abstract][Full Text] [Related]
33. Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity.
Fathallah-Shaykh HM; Gao W; Cho M; Herrera MA
Int J Cancer; 1998 Jan; 75(2):266-76. PubMed ID: 9462718
[TBL] [Abstract][Full Text] [Related]
34. Analysis of mixed lymphocyte-tumor culture in patients with malignant brain tumor.
Yoshida S; Tanaka R; Ono M; Takai N; Saito T
J Neurosurg; 1989 Sep; 71(3):398-402. PubMed ID: 2527972
[TBL] [Abstract][Full Text] [Related]
35. Quantifying the role of immunotherapeutic drug T11 target structure in progression of malignant gliomas: Mathematical modeling and dynamical perspective.
Khajanchi S; Banerjee S
Math Biosci; 2017 Jul; 289():69-77. PubMed ID: 28461156
[TBL] [Abstract][Full Text] [Related]
36. The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model.
Enríquez Pérez J; Fritzell S; Kopecky J; Visse E; Darabi A; Siesjö P
Sci Rep; 2019 Apr; 9(1):5632. PubMed ID: 30948731
[TBL] [Abstract][Full Text] [Related]
37. The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors.
Iorgulescu JB; Ivan ME; Safaee M; Parsa AT
J Neuroimmunol; 2016 Jan; 290():103-8. PubMed ID: 26711578
[TBL] [Abstract][Full Text] [Related]
38. Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era.
Uhm JH; Porter AB
Mayo Clin Proc; 2017 Jun; 92(6):995-1004. PubMed ID: 28578786
[TBL] [Abstract][Full Text] [Related]
39. CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas.
Murphy KA; Griffith TS
Cancers (Basel); 2016 Jul; 8(8):. PubMed ID: 27472363
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Remodeling in Glioma Immune Microenvironment: Intercellular Interactions Distinct From Peripheral Tumors.
Qiu R; Zhong Y; Li Q; Li Y; Fan H
Front Cell Dev Biol; 2021; 9():693215. PubMed ID: 34211978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
